BioNexus Gene Lab Corp. Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss)
BioNexus Gene Lab Corp. (BGLC) reported Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss) of $63.98 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-15.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss · last filed 2025-05-15
- BioNexus Gene Lab Corp. fair value, asset, recurring basis, still held, unrealized gain (loss) for the quarter ending 2025-03-31 was $63.98K.
- BioNexus Gene Lab Corp. fair value, asset, recurring basis, still held, unrealized gain (loss) for the quarter ending 2024-12-31 was -$133.13K.
- BioNexus Gene Lab Corp. fair value, asset, recurring basis, still held, unrealized gain (loss) for the quarter ending 2024-09-30 was $136.53K, a 62.51% decline year-over-year.
- BioNexus Gene Lab Corp. fair value, asset, recurring basis, still held, unrealized gain (loss) for the quarter ending 2024-06-30 was -$32.40K.
- BioNexus Gene Lab Corp. fair value, asset, recurring basis, still held, unrealized gain (loss) for fiscal 2024 was -$69.48K.
- BioNexus Gene Lab Corp. fair value, asset, recurring basis, still held, unrealized gain (loss) for fiscal 2023 was -$306.61K, a 534.13% decline from fiscal 2022.
- BioNexus Gene Lab Corp. fair value, asset, recurring basis, still held, unrealized gain (loss) for fiscal 2022 was $70.63K, a 136.61% increase from fiscal 2021.
- BioNexus Gene Lab Corp. fair value, asset, recurring basis, still held, unrealized gain (loss) for fiscal 2021 was $29.85K.
| Period end | Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss) 3 month | Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss) 3 month as first filed | Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss) 6 month | Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss) 6 month as first filed | Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss) 9 month | Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss) 9 month as first filed | Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss) 12 month | Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | $63.98K 10-Q · filed 2025-05-15 | -$69.14K derived: sum of 2 quarters · filed 2025-05-15 | $67.39K derived: sum of 3 quarters · filed 2025-05-15 | $34.99K derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2024-12-31 | -$133.13K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $3.41K derived: sum of 2 quarters · filed 2025-04-15 | -$28.99K derived: sum of 3 quarters · filed 2025-04-15 | -$69.48K 10-K · filed 2025-04-15 | ||||
| 2024-09-30 | $136.53K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-15 | $104.14K derived: sum of 2 quarters · filed 2024-11-15 | $63.65K 10-Q · filed 2024-11-15 | -$466.25K derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2024-06-30 | -$32.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$72.88K 10-Q · filed 2024-08-14 | -$602.78K derived: sum of 3 quarters · filed 2025-05-15 | -$238.64K derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2024-03-31 | -$40.49K 10-Q · filed 2025-05-15 | $40.49K 10-Q · filed 2024-05-15 | -$570.39K derived: sum of 2 quarters · filed 2025-05-15 | -$206.24K derived: sum of 3 quarters · filed 2025-05-15 | -$384.50K derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | -$529.90K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | -$165.75K derived: sum of 2 quarters · filed 2025-04-15 | -$344.01K derived: sum of 3 quarters · filed 2025-04-15 | -$306.61K 10-K · filed 2025-04-15 | -$313.86K 10-K · filed 2024-04-16 | |||
| 2023-09-30 | $364.15K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-15 | $185.88K derived: sum of 2 quarters · filed 2024-11-15 | $223.28K 10-Q · filed 2024-11-15 | $422.60K derived: sum of 4 quarters · filed 2024-11-15 | ||||
| 2023-06-30 | -$178.26K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$140.86K 10-Q · filed 2024-08-14 | $140.86K 10-Q · filed 2023-08-16 | $58.45K derived: sum of 3 quarters · filed 2024-08-14 | -$7.03K derived: sum of 4 quarters · filed 2024-08-14 | |||
| 2023-03-31 | $37.40K 10-Q · filed 2024-05-15 | $236.71K derived: sum of 2 quarters · filed 2024-05-15 | $171.23K derived: sum of 3 quarters · filed 2024-05-15 | $111.81K derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | $199.31K derived: 10-K 12 month − 10-Q/A 9 month · filed 2024-04-16 | $133.83K derived: sum of 2 quarters · filed 2024-04-16 | $74.41K derived: sum of 3 quarters · filed 2024-04-16 | $70.63K 10-K · filed 2024-04-16 | ||||
| 2022-09-30 | -$65.48K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2024-03-26 | -$124.90K derived: sum of 2 quarters · filed 2024-03-26 | -$128.68K 10-Q/A · filed 2024-03-26 | $128.68K 10-Q · filed 2022-11-14 | -$118.78K derived: sum of 4 quarters · filed 2024-03-26 | |||
| 2022-06-30 | -$59.42K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-16 | -$63.20K 10-Q · filed 2023-08-16 | $63.20K 10-Q · filed 2022-08-15 | -$53.30K derived: sum of 3 quarters · filed 2023-08-16 | -$51.93K derived: sum of 4 quarters · filed 2023-08-16 | |||
| 2022-03-31 | -$3.78K 10-Q · filed 2023-05-09 | $6.12K derived: sum of 2 quarters · filed 2023-05-09 | $7.49K derived: sum of 3 quarters · filed 2023-05-09 | $17.81K derived: sum of 4 quarters · filed 2023-05-09 | ||||
| 2021-12-31 | $9.90K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $11.27K derived: sum of 2 quarters · filed 2023-03-31 | $21.59K derived: sum of 3 quarters · filed 2023-03-31 | $29.85K 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $1.37K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $11.69K derived: sum of 2 quarters · filed 2022-11-14 | $19.95K 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | $10.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $18.58K 10-Q · filed 2022-08-15 | ||||||
| 2021-03-31 | $8.26K 10-Q · filed 2022-05-16 | -$8.26K 10-Q · filed 2021-05-18 | ||||||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $0.00 derived: sum of 2 quarters · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | |||||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |